Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

Lead Sponsor:

National Cancer Institute (NCI)

Conditions:

Childhood Burkitt Lymphoma

Childhood Central Nervous System Germ Cell Tumor

Eligibility:

All Genders

1-21 years

Phase:

PHASE1

Brief Summary

This phase I trial is studying the side effects and best dose of oxaliplatin when given together with irinotecan in treating young patients with refractory solid tumors or lymphomas. Drugs used in che...

Detailed Description

PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose of oxaliplatin when administered with irinotecan in pediatric patients with refractory solid tumors or lymphomas. II. Determine the toxic ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Histologically confirmed refractory malignant solid tumor or lymphoma
  • Intrinsic brain stem tumors and optic pathway tumors do not require histologic verification
  • No known curative therapy or therapy proven to prolong survival with an acceptable quality of life exists
  • Measurable or evaluable disease
  • Evaluable disease is defined as a tumor that cannot be measured using a ruler or calipers, but can be assessed to determine disease progression or complete response, such as any of the following:
  • Positive lesions on metaiodobenzylguanidine (MIBG) or bone scan
  • Metastatic bone marrow disease
  • Elevated tumor markers
  • Presence of a malignant pleural effusion
  • No leukemia
  • Performance status - Karnofsky 50-100% (for patients \> 10 years of age)
  • Performance status - Lansky 50-100% (for patients ≤ 10 years of age)
  • Not specified
  • Absolute neutrophil count ≥ 1,000/mm\^3
  • Platelet count ≥ 100,000/mm\^3 (transfusion independent)
  • Hemoglobin ≥ 8.0 g/dL (transfusion allowed)
  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • ALT ≤ 5 times ULN
  • Albumin ≥ 2 g/dL
  • Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min
  • Creatinine based on age as follows:
  • No greater than 0.8 mg/dL (for patients age 5 and under)
  • No greater than 1.0 mg/dL (for patients age 6 to 10)
  • No greater than 1.2 mg/dL (for patients age 11 to 15)
  • No greater than 1.5 mg/dL (for patients age 16 and over)
  • No arrhythmia on EKG
  • No evidence of dyspnea at rest
  • No exercise intolerance
  • Pulse oximetry \> 94% on room air and no evidence of pulmonary fibrosis by chest radiograph\* or CT scan
  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Weight ≥ 10 kg
  • Neurologic deficits relatively stable for ≥ 1 week before study entry (patients with CNS tumors only)
  • No electrolyte (e.g., sodium, potassium, bicarbonate, calcium, magnesium, and phosphate) abnormality ≥ grade 2 (electrolyte supplementation allowed)
  • No uncontrolled infection
  • No history of life-threatening allergy to camptothecin derivatives or platinum agents
  • No sensory or motor peripheral neuropathy ≥ grade 2
  • No elevation of amylase or lipase ≥ grade 2
  • Able to tolerate enteral medications (e.g., cefixime, cefpodoxime, or loperamide)
  • Recovered from all prior immunotherapy
  • At least 7 days since prior hematopoietic growth factors
  • At least 7 days since prior antineoplastic biologic therapy
  • Prior stem cell transplantation or rescue without total-body irradiation (TBI) allowed provided ≥ 3 months have elapsed and there is no evidence of active graft-versus-host disease
  • No concurrent immunotherapy
  • No concurrent biologic therapy
  • More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) and recovered
  • No prior oxaliplatin
  • No other concurrent chemotherapy
  • Concurrent steroids allowed provided dose has been stable for ≥ 7 days before study entry
  • See Biologic therapy
  • Recovered from all prior radiotherapy
  • At least 2 weeks since prior local palliative small port radiotherapy
  • At least 6 months since prior TBI
  • At least 6 months since prior craniospinal, whole spinal, or whole lung/abdominal radiotherapy
  • At least 6 months since prior radiotherapy to ≥ 50 % of the pelvis
  • At least 6 weeks since other prior substantial radiotherapy to the bone marrow
  • No concurrent radiotherapy
  • No other concurrent investigational drugs
  • No other concurrent anticancer therapy
  • No concurrent cephalosporin antibiotics
  • No concurrent use of any of the following:
  • Phenytoin
  • Carbamazepine
  • Oxcarbazepine
  • Barbiturates
  • Rifampin
  • Phenobarbital
  • Azole antifungal agents
  • Aprepitant
  • Hypericum perforatum (St. John's wort)

Exclusion

    Key Trial Info

    Start Date :

    March 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    Estimated Enrollment :

    24 Patients enrolled

    Trial Details

    Trial ID

    NCT00101270

    Start Date

    March 1 2005

    Last Update

    June 5 2013

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    COG Phase I Consortium

    Arcadia, California, United States, 91006-3776